Identification of a New Morpholine Scaffold as a P2Y12 Receptor Antagonist [PDF]
Molecules, 2016 The P2Y12 receptor is critical for platelet activation and is an attractive drug target for the prevention of atherothrombotic events. Despite the proven antithrombotic efficacy of P2Y12 inhibitors, these thienopyridine scaffolds are prodrugs that lack ...
Young Ha Ahn +6 more
doaj +7 more sources
P2Y12 receptor as a new target for electroacupuncture relieving comorbidity of visceral pain and depression of inflammatory bowel disease [PDF]
Chinese Medicine, 2021 Background The P2Y12 receptor is a kind of purinoceptor that is engaged in platelet aggregation, and P2Y12 inhibitors have been used in clinical antithrombotic therapy. The P2Y12 receptor in microglia induces interleukin-1β (IL-1β) expression, which is a
Yanzhen Li +13 more
doaj +2 more sources
Early treatment with inhibitors of P2Y12 receptor in patients with ST-segment elevation myocardial infarction — 2023 ESC recommendations and scientific evidence. Is clinical evidence sufficient to suggest a move towards precision medicine? The ELECTRA-SIRIO 2 investigators’ viewpoint [PDF]
Cardiology JournalThe 2023 ESC guidelines changed previously recommended a strategy of early treatment in patients with STEMI. Pre-treatment with a P2Y12 receptor inhibitor may be considered in patients undergoing a primary PCI strategy (Class IIb, Level of evidence B ...
Jacek Kubica +31 more
doaj +2 more sources
The effect of P2Y12 receptor inhibitors on clinical outcomes in patients with acute coronary syndrome undergoing primary percutaneous intervention and receiving abciximab [PDF]
Cardiology JournalBACKGROUND: Our study compared the effect of P2Y12 receptor inhibitors in combination with abciximab on clinical outcomes in patients with acute coronary syndrome (ACS).
Onur Altınkaya +9 more
doaj +2 more sources
Real-time platelet P2Y12 receptor occupancy as a promising pharmacodynamics biomarker for bridging the gap between PK/PD of clopidogrel therapy [PDF]
Acta Pharmaceutica Sinica BClopidogrel effectively inhibits platelet aggregation in response to ADP by irreversibly binding to the platelet P2Y12 receptor through its active metabolite. However, the observed discrepancies between the pharmacokinetics (PK) and pharmacodynamics (PD)
Haipeng Li +5 more
doaj +2 more sources
Evidence for a PI3-kinase independent pathway in the regulation of Rap1b activation downstream of the P2Y12 receptor in platelets [PDF]
Platelets, 2022 Platelet activation by adenosine diphosphate (ADP) is mediated through two G-protein-coupled receptors, P2Y1 and P2Y12, which signal through Gq and Gi, respectively.
Carol Dangelmaier, Satya P Kunapuli
doaj +2 more sources
Comparative Long-Term Effect of Three Anti-P2Y12 Drugs after Percutaneous Angioplasty: An Observational Study Based on Electronic Drug Adherence Monitoring [PDF]
Frontiers in Pharmacology, 2017 Aims: Dual platelet inhibition using anti-P2Y12 drugs and aspirin is the standard of care in patients after percutaneous coronary interventions (PCI). Prasugrel and ticagrelor have been shown to be more potent than clopidogrel with less high on-treatment
Valentina Forni Ogna +12 more
doaj +5 more sources
Inhibiting P2Y12 receptor relieves LPS‐induced inflammation and endothelial dysfunction [PDF]
Immunity, Inflammation and Disease, 2022 Xiuxia Han
exaly +2 more sources
Distinct microglial response against Alzheimer's amyloid and tau pathologies characterized by P2Y12 receptor [PDF]
Brain Communications, 2021 Maiko Ono, Bin Ji, Hiroyasu Akatsu
exaly +2 more sources
Applied Sciences, 2021 The P2Y receptor family is a class of G protein-coupled receptors activated primarily by adenosine triphosphate (ATP), adenosine diphosphate (ADP), uridine triphosphate (UTP) and uridine diphosphate (UDP).
Lu Wang +6 more
doaj +1 more source